Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Harnalidge
- Development stage
- Phase 4
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Harnalidge OCAS is an oral formulation of tamsulosin, developed by Astellas Pharma Inc. It is indicated for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Tamsulosin is an alpha-1 adrenergic receptor antagonist, which works by relaxing the muscles in the prostate and bladder neck, thereby improving urine flow and reducing BPH symptoms.
- Brand names
- HarnalidgeHarnalidge OCAS
- Other names
- Tamsulosin OCAS
02
Targets
ADRA1A (α1A)ADRA1D (α1D)ADRA1B (α1B)
Beyond the preview
Go deeper on Harnalidge.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Harnalidge.